Soterix Medical Inc. announces receipt of allowance of claims from the U.S. Patent Office for an application covering Limited Total Energy (LTE) neuromodulation. The claims cover a system and method that allows reduction in power and voltage during brain stimulation, without compromising performance. View the original LTE paper here. LTE has broad applications from various forms of invasive (e.g. Deep Brain Stimulation, Vagus Nerve Stimulation) and non-invasive (transcranial Direct Current Stimulation / tDCS, transcranial Alternating Current Stimulation / tACS, transcranial Pulsed Current Stimulation / tPCS) where LTE provides automatic increased safety without reducing efficacy. LTE is available in Soterix Medical products including the 1x1-LTE, the 1x1-CT, and the REMOTE platform. LTE technology is being used in major ongoing clinical trials including two multi-center trials for major depression (Clinicaltrials.gov Identifiers: NCT01562184 and NCT01894815). LTE is especially useful in applications involving susceptible populations and high-throughput stimulation under various environments (REMOTE).

As described by Mr. Shiraz Macuff, Senior Development Engineer, “The simplest way to understand Limited Total Energy is to consider gears in a car. LTE is gears for neuromodulation- without LTE, undue power is used, which then strains the system. Gears don't change what a device does; it just makes it work better. Based on our experience supporting hundreds of medical centers, LTE was designed with high-throughput use in mind…it is an extra safety factor on our devices that already set the industry standard.”

CAUTION: tDCS is limited by Federal (or United States) law to investigational use only.

BACKGROUND: tDCS- Limited Total Energy (tDCS-LTE) is an exclusive neuromodulation technology developed by Soterix Medical Inc. Invented at The City College of New York, tDCS-LTE is the only tDCS technology optimized for robust low-energy Transcranial Direct Current Stimulation. tDCS-LTE is under investigation in susceptible populations and is made possible through a proprietary adaptive stimulation limiting the voltage and power required for tDCS. It is the only non-invasive neuromodulation technology further optimized for robust deployment in a wide variety of environments including emergency medicine, home-use, etc. Soterix Medical Inc. was formed to develop and deploy innovative medical therapies. Founded in 2008, SMI is the world leader in clinical trials for non-invasive neuromodulation working with over 150 medical centers in the US and worldwide. Click here for a full listing of Soterix Medical clinical trials. SMI has licensed and developed a comprehensive intellectual property portfolio that includes High-Definition transcranial Direct Current Stimulation (HD-tDCS), innovative tDCS technologies, and Neurotargeting. From the most targeted non-invasive clinical systems to the most portable units, Soterix Medical provides clinicians and patients with unique and adaptable solutions. Ongoing Phase I, II, IIb, and III trials use investigational devices that are regulated/limited by US or Federal law.

Complete press release here

Media Contact Kamran Nazim
Tel: +1-888-990-8327
Email: contact@soterixmedical.com